Comparative Pharmacology
Head-to-head clinical analysis: ACTIFED versus NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTIFED versus NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE.
ACTIFED vs NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ACTIFED contains triprolidine, a first-generation antihistamine that competitively inhibits histamine H1 receptors, and pseudoephedrine, a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction and decongestion.
Naphazoline is an alpha-adrenergic receptor agonist that causes vasoconstriction of conjunctival blood vessels, reducing redness and edema. Pheniramine is a histamine H1-receptor antagonist that blocks the effects of histamine, reducing itching and allergic symptoms.
1 tablet (pseudoephedrine HCl 60 mg, triprolidine HCl 2.5 mg) orally every 4-6 hours; maximum 4 tablets in 24 hours.
1-2 drops or sprays in each nostril every 4-6 hours as needed, not to exceed 5-7 days
None Documented
None Documented
Triprolidine: 3.2 hours; Pseudoephedrine: 5–8 hours (pH-dependent: alkaline urine prolongs). Terminal half-life for clinical use typically 4–6 hours.
Naphazoline: Terminal elimination half-life approximately 2-3 hours; clinical effects may persist longer due to local vasoconstriction. Pheniramine: Terminal elimination half-life approximately 14-16 hours; appropriate for twice-daily dosing.
Renal: 80% (20% unchanged, 60% as metabolites). Fecal: 20% (unchanged and metabolites). Active tubular secretion of pseudoephedrine.
Naphazoline: Renal excretion of unchanged drug and metabolites accounts for >80% of elimination. Pheniramine: Renal excretion of unchanged drug and metabolites accounts for >90% of elimination, with <5% biliary/fecal elimination.
Category C
Category C
Decongestant/Antihistamine Combination
Ophthalmic Antihistamine/Decongestant